SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.
Launched by ALDEYRA THERAPEUTICS, INC. · Apr 24, 2017
Trial Information
Current as of May 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female subjects aged ≥ 18 years and ≤ 85 years.
- • Subjects with acute non-infectious anterior uveitis with onset of symptoms within the previous 2 weeks.
- • Best corrected visual acuity (BCVA) better than or equal to 35 letters in the study eye and 65 letters in the non-study eye using ETDRS testing.
- Exclusion Criteria:
- • Have severe/serious ocular pathology in the study eye(s) which may preclude study completion, in the judgement of the Investigator.
- • Active intermediate or posterior uveitis in the study eye(s).
- • Previous anterior uveitis episode in the study eye ≤ 4 weeks prior to screening.
- • Have participated in another investigational device or drug study within 30 days prior to screening.
- • Participation in a prior ADX-102 study.
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for immune-mediated and neurodegenerative diseases. With a focus on leveraging its proprietary technology platform, Aldeyra specializes in the discovery and development of innovative treatments that target the underlying mechanisms of disease. The company’s pipeline includes candidates aimed at addressing conditions such as dry eye disease and other serious ocular disorders, reflecting its commitment to improving patient outcomes through scientific advancement. Aldeyra is driven by a mission to transform the landscape of therapeutic options and enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Dallas, Texas, United States
Irvine, California, United States
Beverly Hills, California, United States
Danbury, Connecticut, United States
Norfolk, Virginia, United States
Winter Haven, Florida, United States
Littleton, Colorado, United States
Houston, Texas, United States
Kansas City, Missouri, United States
Sacramento, California, United States
Baltimore, Maryland, United States
Indianapolis, Indiana, United States
Palisades Park, New Jersey, United States
The Woodlands, Texas, United States
Eugene, Oregon, United States
Fargo, North Dakota, United States
San Antonio, Texas, United States
Birmingham, Michigan, United States
Phoenix, Arizona, United States
Prescott, Arizona, United States
Sun City, Arizona, United States
Waltham, Massachusetts, United States
Birmingham, Alabama, United States
Palo Alto, California, United States
Jacksonville, Florida, United States
Ayer, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials